27 results
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
Le présent document remplace la précédente note de synthèse sur les vaccins anti-hépatite A, publiée par l’OMS en 2012. Il contient des recommandations sur l’utilisation hors indications de...
This document replaces the 2012 WHO position paper on hepatitis A vaccines. It contains off-label recommendations.
COSTVAC is an Excel-based toolkit that provides structured guidance on how to estimate the cost of routine immunization from a sample of health facilities and administrative levels of the health...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
UNIVAC is a single universal vaccine impact and cost-effectiveness decision support model with a standardized, accessible Excel-based (now based in R), interface and a familiar set of input steps and...
Background: Infection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization...
Objectives: To describe and systematically review the modelling and reporting of cost-effectiveness analysis of vaccination in Hong Kong, and to identify areas for quality enhancement in future...
Hepatitis A is a common infectious disease worldwide that was endemic in many regions of Southern Italy, such as Apulia region. After a large hepatitis A outbreak occurred between 1996 and 1997, in...
Vaccines are extremely safe and harm is rare. Worldwide, more than 30 000 vaccine doses are delivered per second through routine immunization programs, which, in turn, prevent an estimated 2...
In November 2005, hepatitis A vaccine was funded under the Australian National Immunisation Program for Aboriginal and Torres Strait Islander (Indigenous) children aged 12–24 months in the targeted...
Background: Single-dose Hepatitis A Virus (HAV) vaccination was implemented in all Argentinean children aged 12 months in 2005. Previous studies demonstrated high prevalence of protective antibody...
Immunization is an important component of preventive healthcare services aiming to prevent and eventually eradicate infectious diseases by immunizing people before they become infected. Although...
Viral hepatitis is a serious health problem all over the world. However, the reduction of the morbidity and mortality due to vaccinations against hepatitis A and hepatitis B has been a major...
Summary
Background
With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention...
OBJECTIVE:
Data on duration and long-term protective effects of hepatitis A vaccines (HepA) have not been reviewed using a systematic approach. Our objective is to provide a comprehensive review of...
As part of the Centers for Disease Control and Prevention’s (CDC) National Notifiable Diseases Surveillance System (NNDSS) (1), viral hepatitis case-reports are received electronically from U.S....
The Viral Hepatitis Prevention Board met in London, UK (June 5–6, 2015), to discuss options towards a future free of viral hepatitis. Hepatitis B vaccine was introduced in 1982 and is now included...
In countries where hepatitis A is highly endemic, exposure to hepatitis A virus (HAV) is almost universal before the age of 10years, and large-scale immunization efforts are not required. In...
Hepatitis A vaccination in early childhood has reduced hepatitis A transmission. Coadministration of hepatitis A vaccine with other childhood vaccines may assist completion of the age-appropriate...
Triangulation of results from two methods captured a richer story behind vaccine adoption decisions for hepatitis A. The discrepancy between policymakers’ beliefs and existing data suggest a...
The study was conducted to further investigate the single-dose approach of hepatitis A vaccination, while providing supportive data on the flexibility of booster administration. Participants received...
This study was performed to determine the priority of vaccine introduction for five vaccine-preventable diseases (VPDs) caused by Haemophilus influenzae type b (Hib), pneumococcus (Spn), hepatitis A...
We conducted a systematic review of the published literature to examine the impact of new vaccine introduction on countries’ immunization and broader health systems. Six publication databases were...
Imported frozen pomegranate arils were identified as the vehicle early in the investigation by combining epidemiology—with data from several sources—genetic analysis of patient samples, and...
The extent to which reporting delays should be reduced to gain substantial improvement in outbreak control is unclear. We developed a model to quantitatively assess reporting timeliness. Using...
MI4A produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies identify areas of risk for sustainable access to vaccine supply and...